Continue Rosuvastatin 5 mg Daily
Yes, continue rosuvastatin 5 mg daily, as the patient has achieved excellent LDL-C control at 69 mg/dL, which is well below most treatment targets, and the medication is clearly effective and well-tolerated at this dose 1.
Rationale for Continuation
LDL-C Goal Achievement
Your patient's LDL-C of 69 mg/dL represents substantial reduction from baseline and meets virtually all guideline-recommended targets. The 2018 ACC/AHA guidelines emphasize that statin therapy should be continued when patients achieve their LDL-C goals, with reassessment of the risk-benefit ratio 2. The FDA labeling confirms that rosuvastatin 5 mg is an appropriate maintenance dose within the 5-40 mg therapeutic range 1.
Monitoring Schedule
According to the 2016 ESC/EAS guidelines, once a patient reaches target lipid levels, annual monitoring is sufficient unless adherence issues or other specific concerns arise 3. You should:
- Recheck lipids annually
- Monitor liver enzymes (ALT) only if symptoms of hepatotoxicity develop
- Check creatine kinase (CK) only if the patient develops muscle symptoms
- Do not perform routine CK or transaminase monitoring in asymptomatic patients 2, 3
Additional Lipid Profile Considerations
HDL-C of 44 mg/dL: While slightly below optimal (>40 mg/dL for men, >50 mg/dL for women), this is acceptable. Rosuvastatin 5 mg has been shown to increase HDL-C by 8-13% 4, and continued therapy may provide further modest improvements 5.
Triglycerides of 158 mg/dL: This is within acceptable range (<150 mg/dL is optimal, but <200 mg/dL is acceptable). Rosuvastatin effectively reduces triglycerides, with studies showing 16% reductions at the 5 mg dose 4.
Key Clinical Pitfalls to Avoid
Do Not Discontinue Effective Therapy
A common error is stopping statins when lipid goals are achieved. The benefit of statins comes from sustained LDL-C reduction over time, which translates to reduced cardiovascular events and mortality 2. Discontinuation would eliminate this protection.
Do Not Increase Dose Unnecessarily
Since the patient has achieved excellent LDL-C control, dose escalation is not indicated. Higher doses increase the risk of statin-associated side effects without additional benefit when goals are already met 2, 3.
Assess for Statin-Associated Side Effects
At each visit, specifically ask about:
- Muscle symptoms (myalgia, weakness, cramping)
- New-onset fatigue
- Any symptoms suggesting hepatotoxicity
If muscle symptoms develop, measure CK levels. If CK is <4× upper limit of normal and symptoms are mild, continue therapy while monitoring 3.
Long-term Management Strategy
Annual reassessment should include:
- Fasting lipid panel
- Assessment of adherence
- Evaluation for any new medications that may interact with rosuvastatin 1
- Discussion of lifestyle modifications (diet, exercise, weight management) to optimize cardiovascular risk reduction 2
The patient's current regimen represents optimal medical therapy with documented efficacy and safety at this dose 6, 4.